Literature DB >> 15362604

Nephrotoxic effects of X-ray contrast media.

Erik Andrew1, Knut J Berg.   

Abstract

The annual sale of x-ray contrast media (CM) now represents 60 million doses, and contrast nephropathy (CN) has been the third-leading cause of hospital-acquired acute renal failure. In this review article, physicochemical, pharmacokinetic, and pharmacodynamic properties of CM are surveyed. The definition of CN is presented, as well as the mechanisms involved in the pathogenesis. Low osmolar monomeric CM (LOCM) are less nephrotoxic than the older ionic high osmolar CM (HOCM), but in risk patients the incidence of CN is still high after intravascular administration of LOCM. Non-ionic dimeric CM are iso-osmolar to plasma (IOCM), and they have reduced the nephrotoxicity even more than LOCM. The most important risk factors for CN are diabetes mellitus and impaired renal function. Selection of patients, hydration, and type of CM are essential for prevention and prophylaxis of CN. We do not recommend routine prophylaxis with N-acetylcysteine (NAC) during CM investigations, but its use in high-risk patients should be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362604     DOI: 10.1081/clt-120037430

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  3 in total

Review 1.  Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review.

Authors:  Martin R Tramèr; Erik von Elm; Pierre Loubeyre; Conrad Hauser
Journal:  BMJ       Date:  2006-07-31

2.  Effects of carperitide on contrast-induced acute kidney injury with a minimum volume of contrast in chronic kidney disease patients.

Authors:  Naoki Okumura; Mutsuharu Hayashi; Enyu Imai; Hideki Ishii; Daiji Yoshikawa; Yoshinari Yasuda; Motomitsu Goto; Seiichi Matsuo; Yutaka Oiso; Toyoaki Murohara
Journal:  Nephron Extra       Date:  2012-12-11

3.  Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma.

Authors:  Naoto Fujiwara; Ryosuke Tateishi; Masaaki Akahane; Masataka Taguri; Tatsuya Minami; Shintaro Mikami; Masaya Sato; Koji Uchino; Kouji Uchino; Kenichiro Enooku; Yuji Kondo; Yoshinari Asaoka; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Kuni Ohtomo; Kazuhiko Koike
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.